论文部分内容阅读
Introduction In China microtransplantation hematopoietic stem cells (microHSCT) was used in a population as a consolidation of patients with AML in first complete remission (AML-CR1) with no HLA-identical donors.Mei Guo and colleagues published a study which shows that microtransplantation as a new treatment for patients with AML may have a significant antitumor effect and reduce treatment-related toxicity,which improves survival in this group of patients.